What do we mean by validating a prognostic model, pp.453-73, 2000. ,
PROSTATE SPECIFIC ANTIGEN DOUBLING TIME AS A SURROGATE END POINT FOR PROSTATE CANCER SPECIFIC MORTALITY FOLLOWING RADICAL PROSTATECTOMY OR RADIATION THERAPY, The Journal of Urology, vol.172, issue.5, pp.42-46, 2004. ,
DOI : 10.1097/01.ju.0000141845.99899.12
Determining the number of components in mixtures of linear models, Computational Statistics & Data Analysis, vol.38, issue.1, pp.15-48, 2001. ,
DOI : 10.1016/S0167-9473(01)00017-2
Survival Model Predictive Accuracy and ROC Curves, Biometrics, vol.9, issue.1, pp.92-105, 2005. ,
DOI : 10.1093/biostatistics/kxh013
Joint modelling of longitudinal measurements and event time data, Biostatistics, vol.1, issue.4, pp.465-80, 2000. ,
DOI : 10.1093/biostatistics/1.4.465